AAAAAA

   
Results: 1-11 |
Results: 11
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study
Authors: Gaynor, ER Unger, JM Miller, TP Grogan, TM White, LA Mills, GM Balcerzak, SP Varterasian, M LeBlanc, M Fisher, RI
Citation: Er. Gaynor et al., Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study, J CL ONCOL, 19(3), 2001, pp. 750-755
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease
Authors: Press, OW LeBlanc, M Lichter, AS Grogan, TM Unger, JM Wasserman, TH Gaynor, ER Peterson, BA Miller, TP Fisher, RI
Citation: Ow. Press et al., Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease, J CL ONCOL, 19(22), 2001, pp. 4238-4244
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovariancarcinoma: A gynecologic oncology group study
Authors: Fracasso, PM Brady, MF Moore, DH Walker, JL Rose, PG Letvak, L Grogan, TM McGuire, WP
Citation: Pm. Fracasso et al., Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovariancarcinoma: A gynecologic oncology group study, J CL ONCOL, 19(12), 2001, pp. 2975-2982
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
Authors: Tubbs, RR Pettay, JD Roche, PC Stoler, MH Jenkins, RB Grogan, TM
Citation: Rr. Tubbs et al., Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message, J CL ONCOL, 19(10), 2001, pp. 2714-2721
Response: Expression of VEGF in myelodysplasia
Authors: Bellamy, WT Grogan, TM List, AF
Citation: Wt. Bellamy et al., Response: Expression of VEGF in myelodysplasia, BLOOD, 98(4), 2001, pp. 1272-1273
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
Authors: Bellamy, WT Richter, L Sirjani, D Roxas, C Glinsmann-Gibson, B Frutiger, Y Grogan, TM List, AF
Citation: Wt. Bellamy et al., Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes, BLOOD, 97(5), 2001, pp. 1427-1434
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features
Authors: Braziel, RM Arber, DA Slovak, ML Gulley, ML Spier, C Kjeldsberg, C Unger, J Miller, TP Tubbs, R Leith, C Fisher, RI Grogan, TM
Citation: Rm. Braziel et al., The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features, BLOOD, 97(12), 2001, pp. 3713-3720
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma
Authors: Stopeck, AT Gessner, A Miller, TP Hersh, EM Johnson, CS Cui, HY Frutiger, Y Grogan, TM
Citation: At. Stopeck et al., Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma, CLIN CANC R, 6(10), 2000, pp. 3904-3909
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival
Authors: Grogan, TM Fenoglio-Prieser, C Zeheb, R Bellamy, W Frutiger, Y Vela, E Stemmerman, G Macdonald, J Richter, L Gallegos, A Powis, G
Citation: Tm. Grogan et al., Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival, HUMAN PATH, 31(4), 2000, pp. 475-481
The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma
Authors: Rimsza, LM Campbell, K Dalton, WS Salmon, S Willcox, G Grogan, TM
Citation: Lm. Rimsza et al., The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma, LEUK LYMPH, 34(3-4), 1999, pp. 315
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
Authors: Bellamy, WT Richter, L Frutiger, Y Grogan, TM
Citation: Wt. Bellamy et al., Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies, CANCER RES, 59(3), 1999, pp. 728-733
Risultati: 1-11 |